Clinical application of Apatinib in the treatment of malignancies / 国际肿瘤学杂志
Journal of International Oncology
; (12): 45-48, 2019.
Article
em Zh
| WPRIM
| ID: wpr-743086
Biblioteca responsável:
WPRO
ABSTRACT
Apatinib is a kind of antiangiogenesis drug of small molecular tyrosine kinase inhibitor, which can strongly against tumor angiogenesis by inhibiting vascular endothelial growth factor receptor 2 with highly selectivity. Apatinib can block cell cycle and reverse drug resistance. Clinical studies have shown that Apatinib is effective for many malignant tumors,including non-small cell lung cancer,breast cancer and gastric cancer,which has encouraging objective response rate and survival benefit. Apatinib also has good safety and tolerance.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of International Oncology
Ano de publicação:
2019
Tipo de documento:
Article